K2/SPICE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

K2/spice refers to a class of chemicals called synthetic cannabinoids. These chemicals are made in the lab and are similar to chemicals found in cannabis.

Over 100 different synthetic cannabinoids have been identified. When K2/spice is inhaled, it attaches to proteins in the body known as cannabinoid receptors. This causes a "high." But K2/spice binds to these receptors much better than the chemicals naturally found in cannabis. This can lead to serious side effects.

Some people smoke K2/spice to get high. Smoking K2/spice can cause harmful side effects, including death. There is no good scientific evidence to support any use.

Due to serious safety concerns, synthetic cannabinoids are banned in many states. Despite this, new synthetic cannabinoids continue to be developed. Some CBD and cannabis products have been found to be contaminated with synthetic cannabinoids. Don't confuse K2/spice with natural cannabinoids, including CBD, Cannabichromene (CBC), Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabinol (CBN), and Tetrahydrocannabivarin (THCV). Also don't confuse it with cannabis or hemp. These are not the same.

Uses & Effectiveness ?

We currently have no information for K2/SPICE overview.

Side Effects

When inhaled: K2/spice is unsafe. It can cause serious side effects, including hallucinations, seizures, kidney failure, heart attacks, stroke, and death.

Special Precautions and Warnings

When inhaled: K2/spice is unsafe. It can cause serious side effects, including hallucinations, seizures, kidney failure, heart attacks, stroke, and death.

Pregnancy and breast-feeding: K2/spice is unsafe when used during pregnancy and breast-feeding. K2/spice has many harmful side effects. It might interfere with fertility and the growth of the fetus during pregnancy.

Heart disease: K2/spice might increase the chance for heart attacks and death in people with heart disease. Avoid use.

Kidney disease: K2/spice might harm the kidneys in people with kidney disease. Avoid use.

Schizophrenia: K2/spice might increase the chance for agitation, hallucinations, and other symptoms of schizophrenia in people with schizophrenia. Avoid use.

Seizure disorders: K2/spice might cause more seizures in people with seizure disorders such as epilepsy. Avoid use.

Interactions ?

Moderate Interaction

Be cautious with this combination

Medications used to prevent seizures (Anticonvulsants) interacts with K2/SPICE
K2/spice may increase the risk of seizures. Therefore, taking K2/spice may decrease the effects of medications used to prevent seizures. This might increase the risk of seizures.
Medications that can cause an irregular heartbeat (QT interval-prolonging drugs) interacts with K2/SPICE
K2/spice might affect electrical currents in the heart. This can increase the risk of having an irregular heartbeat. Some medications can have this same effect. Taking K2/spice with these medications might increase the risk for a serious heart issue.

Dosing

K2/spice is the general term used for synthetic cannabinoids. Over 100 synthetic cannabinoids have been identified. Synthetic cannabinoids have been banned in many states, but new synthetic cannabinoids continue to be developed.

Some people smoke K2/spice to get high. Smoking K2/spice can cause harmful side effects, including death.

View References

REFERENCES:

Ahmed ST, Alam A, Hassan A, Kamal S, Mahmood M. Acute Liver Failure Caused by Synthetic Marijuana Use. Am J Ther. 2020. doi: 10.1097/MJT.0000000000001181. View abstract.

Ahmed T, Khan A, See VY, Robinson S. Cardiac arrest associated with synthetic cannabinoid use and acquired prolonged QTc interval: A case report and review of literature. HeartRhythm Case Rep. 2020;6(5):283-286. View abstract.

Amar JY, Ruta J, Rahimian D, Dillinger RL, Katz P. Toxic leukoencephalopathy with extrapyramidal dysfunction due to synthetic cannabinoids. J Clin Neurosci 2018;58:213-4. View abstract.

Andonian DO, Seaman SR, Josephson EB. Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication - a case series. Am J Emerg Med 2017;35(6):940.e5-940.e6. View abstract.

Boland DM, Reidy LJ, Seither JM, Radtke JM, Lew EO. Forty-Three Fatalities Involving the Synthetic Cannabinoid, 5-Fluoro-ADB: Forensic Pathology and Toxicology Implications. J Forensic Sci. 2020;65(1):170-182. View abstract.

Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2014;46(1):72-85. View abstract.

Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12-41. View abstract.

Chinnadurai T, Shrestha S, Ayinla R. A curious case of inhalation fever caused by synthetic cannabinoid. Am J Case Rep 2016;17:379-83. View abstract.

Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr 2015;167(3):757-61.e1. View abstract.

Cohen K, Mama Y, Rosca P, Pinhasov A, Weinstein A. Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility. Front Psychiatry. 2020;11:602. View abstract.

D'Errico S, Zanon M, Radaelli D, et al. Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers. Biomedicines 2022;10(8):1936. View abstract.

Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol (Phila). 2020;58(5):368-374. View abstract.

Davidson C, Opacka-Juffry J, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, Molina-Holgado F. Spicing up pharmacology: a review of synthetic cannabinoids from structure to adverse events. Adv Pharmacol 2017;80:135-68. View abstract.

Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses 2015;8(4):205-8. View abstract.

Fatmi SS, Outlaw A. Coronary Vasospasm Associated With Synthetic Marijuana Resulting in Transient Electrocardiogram Changes and Troponin Elevation. Cureus 2022;14(5):e25084. View abstract.

Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana "spice". Neurology 2013;81(24):2090-3. View abstract.

Gala Z, Kravchenko T, Volk L, Chatani P, Kar R, Choron RL. Subcutaneous Emphysema, Pneumothorax, Pneumomediastinum, and Pneumoperitoneum Following Synthetic Cannabinoid Toxicity in an Incarcerated Man. Am Surg 2022. View abstract.

Godwin PO, Unterman S, Elfessi ZZ, Bhagat JD, Kolman K. Management of Rodenticide Poisoning Associated with Synthetic Cannabinoids. Fed Pract. 2019;36(5):237-241. View abstract.

Hvozdovich JA, Chronister CW, Logan BK, Goldberger BA. Case Report: Synthetic Cannabinoid Deaths in State of Florida Prisoners. J Anal Toxicol. 2020;44(3):298-300. View abstract.

Jafry AH, LaGrow A, Akhtar KH, et al. Synthetic cannabinoids and ST elevation myocardial infarction. Am J Med Sci 2022;364(4):481-491. View abstract.

Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med 2018;379(13):1216-23. View abstract.

Kourouni I, Mourad B, Khouli H, Shapiro JM, Mathew JP. Critical Illness Secondary to Synthetic Cannabinoid Ingestion. JAMA Netw Open. 2020;3(7):e208516. View abstract.

Lamy FR, Daniulaityte R, Nahhas RW, et al. Increases in synthetic cannabinoids-related harms: results from a longitudinal web-based content analysis. Int J Drug Policy. 2017;44:121-9. View abstract.

Law R, Schier J, Martin C, Chang A, Wolkin A; Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use - United States, January-May 2015. MMWR Morb Mortal Wkly Rep 2015;64(22):618-9. View abstract.

Manini AF, Krotulski AJ, Schimmel J, et al. Respiratory failure in confirmed synthetic cannabinoid overdose. Clin Toxicol (Phila). 2022;60(4):524-526. View abstract.

Martínez L, La Maida N, Papaseit E, et al. Acute pharmacological effects and oral fluid concentrations of the synthetic cannabinoids JWH-122 and JWH-210 in humans after self-administration: an observational study. Front Pharmacol. 2021 Aug 19;12:705643. View abstract.

McIlroy G, Ford L, Khan JM. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol 2016;17:2. View abstract.

Monte AA, Calello DP, Gerona RR, et al. Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC database study. J Med Toxicol 2017;13(2):146-52. View abstract.

Öztürk E, Oral A, Özdemir M, Bambul N. Synthetic marijuana "K2" induced ITP. Platelets 2015;26(3):258-9. View abstract.

Parajuli P, Regmi MR, Lara-Garcia OE, Abu Limon I, Deckard A. Man vs. man-made marijuana: A case of drug-induced posterior reversible encephalopathy syndrome (PRES) due to K2, a synthetic cannabinoid (SCB). J Community Hosp Intern Med Perspect. 2020;10(4):361-364. View abstract.

Poklis JL, Mulder HA, Peace MR. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int. 2019 Jan;294:e25-e27. Epub 2018 Nov 1. View abstract.

Rianprakaisang T, Gerona R, Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clin Toxicol (Phila). 2020;58(3):215-216. View abstract.

Ruiz-Maldonado TM, Dorey A, Christensen ED, Campbell KA. Near-fatal spice intoxication of a toddler. Pediatrics. 2021 Aug;148(2):e2021050888. View abstract.

Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 2015;48(5):573-80. View abstract.

Sheikh IA, Luksic M, Ferstenberg R, Culpepper-Morgan JA. Spice/K2 synthetic marijuana-induced toxic hepatitis treated with N-acetylcysteine. Am J Case Rep 2014;15:584-8. View abstract.

Simon G, Tóth D, Heckmann V, Kuzma M, Mayer M. Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA. Leg Med (Tokyo). 2022 Feb;54:102004. View abstract.

Skryabin VY, Vinnikova MA. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids. J Psychiatr Pract. 2019 Nov;25(6):485-490. View abstract.

Stogner J, Patterson C. Suicidal ideation, planning, and attempts among synthetic cannabinoid users across different demographic subgroups. Crisis. 2022;43(4):323-330. View abstract.

Sun X, Dey SK. Synthetic cannabinoids and potential reproductive consequences. Life Sci 2014;97(1):72-7. View abstract.

Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016;54(1):1-13. View abstract.

Theunissen EL, Reckweg JT, Hutten NRPW, et al. Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. Pharmacol Biochem Behav. 2021 Mar;202:173118. View abstract.

Tse R, Kodur S, Squires B, Collins N. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J 2014;44(9):934-6. View abstract.

Yamanoglu A, Cakmak S, Celebi Yamanoglu NG, Sogut O. A new side effect of synthetic cannabinoid use by the bucket (waterpipe) method: acute respiratory distress syndrome (ARDS). Turk J Emerg Med 2017;18(1):42-4. View abstract.

Yamanoglu A, Celebi Yamanoglu NG, Evran T, Sogut O. How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use. J Clin Ultrasound 2018;46(9):605-9. View abstract.

Yeniocak S, Kalkan A, Yamanoglu A, Öztürk S, Sögüt Ö, Metiner M. The effects of synthetic cannabinoids on the cardiovascular system: A case-control study. Turk J Emerg Med. 2021;21(4):198-204. View abstract.

Yildiz SS, Sutasir MN, Sigirci S, et al. Acute effects of synthetic cannabinoids on ventricular repolarization parameters. Turk Kardiyol Dern Ars. 2019;47(5):384-390. View abstract.

Zheng CY, Minniti CP, Chaitowitz MH. Sickle cell crisis complicated by synthetic cannabinoid abuse: a case report. Hemoglobin 2016;40(3):220-2. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.

Conditions

Drugs & Supplements

Well-Being

More

K2/SPICE - Uses, Side Effects, and More